Home
overview

 

What is this event about?

 

 

 

 

About the conference

Following the tremendous successes of our previous KOL/MSL conferences in London, Munich and Stockholm over the past four years, SMi are proud to present the latest event in our UK KOL and MSL portfolio - Key Opinion Leader Liaison and MSL Best Practice.

The conference will focus on the issues facing those involved in Medical Affairs and the increasingly varied role of Medical Science Liaisons, from their traditional function working with Key Opinion Leaders to the newer functions and challenges associated with the role.

The interaction between key academics/physicians and the pharmaceutical industry is a vital part of any marketing strategy to commercialize a new drug and bring it to market. The building of relationships between pharma and such key opinion leaders can be both challenging and rewarding for all involved. However, with controversy surrounding these interactions, the conference aims to focus on getting the relationship right and exploring the limits of such collaboration.

With leading KOLs giving their perspective, alongside discussions from those in pharma tasked with forging these relationships and, crucially, the end-purchasers from national health departments, this conference will seek to provide a comprehensive overview of the area; the challenges facing those within it, developments over the past year and assessments of what the future may bring.

Allowing for plenty of discussion within the agenda this conference is unique in providing an ideal platform to obtain the building blocks needed for successful KOL interactions and MSL programmes, while offering networking opportunities throughout the day.

Help to dispel some of the myths that have distorted the public perception of these relationships by participating in healthy debate and discussion about the way to move forward with these essential exchanges!

 

Why not attend the associated workshop as well?

Associated with the conference there will be a one day workshop taking place on 27th September

Led by leaders in their field, our workshops are an excellent opportunity to explore in a more intimate and interactive setting issues which will be discussed at the conference. 

Fancy speaking at the conference?  Do you know of anyone who may be interested in speaking?  We are always on the look-out for new speakers for our upcoming conferences.  Let us know - contact the Conference Producer.

For sponsorship and exhibitioning opportunities, contact our Sponsorship Department.

 

How you will benefit

Hear from some of the leading experts in identifying, approaching and managing KOLs and KOL programmes

Learn how to increase your ROI by having a strategic and structured MSL programme

Navigate the increasingly diverse role of the MSL and take back to you work new approaches to achieve success

Discover the best ways to manage your medical and scientific advice output for the long-term benefit of your brand

Network with MSLs, KOLs, industry leaders, government and medical communication agencies

 

 Who should attend this event?

Chief Executives, Vice Presidents, Heads, Directors, and Project Leaders of

  • Medical Science Liaisons, MSLs
  • Medical Affairs, Scientific Affairs
  • Medical Advisors, Scientific Advisors
  • KOL Development, KOL Relationships
  • Key Opinion Management
  • External Speaker Faculty Management
  • Medical Communications
  • Clinical Outcomes
  • Scientific Affairs
  • Medical Education
  • External Stakeholder Management/Liaison
  • Programme/Product/Brand Management
  • Marketing
  • Professional Education

Delegates at our KOL event in Munich in June 2010 came from across the world... Join the wide range of high level delegates again at our event in 2011..

Graph of delegate countries

  

Previous attendees and participants have come from organizations including:

 

  • Shire
  • Pfizer
  • Grunenthal 
  • Boehringer Ingelheim
  •  Nycomed
  • Innogenetics
  • European Parkinsons Disease Association
  • Merck
  • Leo Pharma 
  • Eli Lilly
  • AstraZeneca
  • Association of the British Pharmaceutical Industry
  • Genzyme
  • Kings College, London
  • Bristol-Myers Squibb
  • UCB Gmbh
  • Novartis
  • Bayer Schering Pharma
  • MedImmune
  • Amgen
  • Harvard Medical School 
  • GSK
  • Sanofi-Aventis 
  • Abbott
  • Napp Pharmacueticals
  • Mederi
  • Caudex Medical
  • Tachris AG
  • Celgene International
  • Biogen Idec International
  • University College London
  • British Medical Journal
  • Norgine 
  • Vifor Pharma

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Neil Kendle

Neil Kendle, Managing Director, Kendle Healthcare

9:10 All change in the relationships between industry and academic clinicians?

  • New types of engagement in R&D
  • New marketing paradigms and roles for clinical leaders
  • New media for messaging and networking
  • New levels of transparency
  • A new contract?
  • Richard Barker

    Richard Barker, Director, Oxford Centre for Accelerating Medical Innovations

    9:55 A new KOL model in the rare diseases area

    Petr Seidl

    Petr Seidl, Medical Director, Genzyme C E G

  • Assessing the landscape and key drivers
  • Disease management as a natural platform for long-term co-operation with KOLs
  • Reaching new levels of quality in interactions with KOLs
  • Introducing an integrated model of KOL liaison in the orphan diseases area
  • Learning points and transferability
  • 10:40 Morning Coffee

    11:10 Reflecting on the ethics of relationships between KOLs and pharmaceutical companies

    Sian Walker

    Sian Walker, Director, Pharmaceuticalethics.com

    11:50 Assessing the impact of the Bribery Act on relationships between pharmaceutical companies and KOLs in the UK

    Rosanna Cooper

    Rosanna Cooper, Global Head, RT Coopers

  • Overview of the main aspects of the Bribery Act likely to effect the pharmaceutical industry in its relationships with KOLs
  • How is the Act likely to be interpreted and what will be the practical implications for KOL liaisons?
  • What will need to change in order to ensure relationships are conducted in a legal manner?
  • 13:20 Networking Lunch

    14:20 Market Access and KOL Engagement in Germany

    Maximilian Gabler

    Maximilian Gabler, Head of Policy Operations, Bayer Vital GmbH

  • German drug reimbursement legislation: dawn of the gods for the whole of Europe?
  • Access and success: how to engage with KOLs from a market access perspective
  • Advocacy and access: what makes a KOL and what does not
  • From KOL manager to KOL coach: the new customer, the new partner, the new message
  • New pharma: the payer perspective and scientific marketing
  • 15:05 What is a KOL and how do you know one when you see them?

    Christian Felter

    Christian Felter, Associate Director, Medical Affairs, Astellas Pharma Europe

  • What is a KOL and are they really KEE or another TLA?
  • How can you identify a rising star?
  • The importance of diversity in KOL relationships in an international market
  • 15:50 Chairman’s Closing Remarks

    Neil Kendle

    Neil Kendle, Managing Director, Kendle Healthcare

    16:00 Afternoon Tea

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Neil Kendle

    Neil Kendle, Managing Director, Kendle Healthcare

    9:10 Establishing the role and responsibilities of MSLs within a pharmaceutical organization

    David Gillen

    David Gillen, Head of International Medical Affairs, Gilead Sciences Ltd

  • What are the needs of pharma's customer base, and how does this affect MSL strategy?
  • Defining MSL remits and competencies: what profile of MSL is needed?
  • Identifying the ideal number of MSLs for your requirements
  • MSLs and interface management: who do MSLs need to work with? When?
  • Precise details to be confirmed
  • 9:50 Measuring the ROI of KOL mapping exercises

    Peter Joshua

    Peter Joshua, Partner, Medical Marketing Research International

  • How can the ROI of a KOL mapping research study be assessed?
  • How much better is independent KOL identification than in-house 'collective wisdom'?
  • Is it worth the fees being asked?
  • 10:30 Morning Coffee

    11:00 The lifecycle management of key opinion leaders from Phase I to the end of exclusivity

    Rav Seeruthun

    Rav Seeruthun, Head of Clinical Affairs, Napp Pharmaceuticals Ltd

  • Maintaining relationships with KOLs - the increasing importance of early-stage development KOLs
  • How have changes to the regulatory environment affected relationships between pharma and KOLs?
  • The clinical oxymoron of Phase II and III: early data, but avoiding failed trials - how can KOLs help?
  • A joined-up, holistic approach to KOLs from Phase IIIB and beyond
  • 11:40 Interactive Session: Deciphering the 'grey' and identifying best practice for your field-based medical liaison (MSL) role

  • Presenting first-hand MSL experiences where compliant behaviour / best practice is not always clear
  • This session will involve delegate participation / voting to identify which course of action would be taken
  • Reflecting on delegate experiences / operating procedures to highlight commonality and areas of best practice
  • Helping to identify boundaries / compliant opportunities for your non-promotional field-based medical liaison
  • Mo Lewes

    Mo Lewes, Senior Medical Liaison Manager, UK and Republic of Ireland, Boehringer Ingelheim

    Fiona Grant

    Fiona Grant, Medical Function Lead, Roche Products

    Rav Seeruthun

    Rav Seeruthun, Head of Clinical Affairs, Napp Pharmaceuticals Ltd

    12:40 Networking Lunch

    13:40 Cross-country/regional KOL management

    Eddy Wu

    Eddy Wu, Medical Director, Novartis Pharmaceuticals

  • How can resources be maximized?
  • Assessing collaborations between local and regional/global organizations
  • Building a roadmap of KOL development: from local to regional and global
  • Facing the challenges for smaller organizations
  • 14:20 Establishing effective internal communication and co-ordination of KOL Engagement

    Neil Kendle

    Neil Kendle, Managing Director, Kendle Healthcare

  • Co-ordinating KOL engagement between global functions and affiliates
  • Assigning responsibilities and ensuring effective co-operation between scientific and commercial functions
  • Planning global and affiliate KOL engagement to stay within a 'fees for services' cap, prospectively not retrospectively
  • Segmenting KOL listings and advocacy mapping to ensure effective choice of KOLs across geographies
  • 15:00 Chairman’s Closing Remarks

    Neil Kendle

    Neil Kendle, Managing Director, Kendle Healthcare

    15:10 Afternoon Tea

    15:45 Close of Conference

    +

    Workshops

    Opinion Leader Development
    Workshop

    Opinion Leader Development

    Copthorne Tara Hotel
    27th September 2011
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.